Germany's FDP Calls For Higher Patient Contributions

3 March 1997

German Liberal Party (FDP) health spokesman Dieter Thomae has called forhigher patient contributions to health care costs, amid a growing argument inside the Bonn coalition government parties as to whether spending increases can be funded by patients and insured people alone.

Mr Thomae rejected suggestions of a split, saying the parties are united over all questions of health service structure. The point has now been reached, he said, where it must be made clear to people that without increased contributions to costs, the health service can no longer be properly funded.

Meanwhile, the health experts of the Christian Democrats (CDU) and the FDP appear agreed on a range of issues including that of drug prescription volume - effectively that of pack size guidelines. They maintain that under the changes to health insurance regimes, doctors and health funds would be obliged to control their drug budgets through a unified system of medically-determined volume guidelines applicable to each prescribing doctor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight